Prospective evaluation of oxygen saturation endoscopic imaging for radiotherapy response in head and neck cancer
Abstract Background We developed an endoscopic imaging technology, oxygen saturation imaging (OS imaging), to assess real-time tissue oxygenation levels. However, its clinical impact remains unclear. This prospective observational study evaluated the association between pretreatment tumor oxygen saturation (StO 2 ) quantified by OS imaging and the outcomes of patients with head and neck squamous cell carcinoma (HNSCC) receiving radiotherapy (RT). Methods The primary endpoint was the association between pretreatment tumor StO 2 and complete response rate at 8 weeks after RT completion. Secondary endpoints were the impact of StO 2 on 1-year overall survival, progression-free survival, and local failure rates. Results Of 50 patients with HNSCC enrolled from 2019 to 2022, 42 who underwent RT and OS imaging are analyzed. Of those, 41 received concurrent platinum-based chemotherapy. Median pretreatment StO 2 is significantly lower in tumor tissue than in normal mucosa (61% vs. 66%, respectively). Complete response rates at 8 weeks after RT are not significantly different between the hypoxia (StO 2 ≤ 61%, n = 22) and non-hypoxia (StO 2 > 61%, n = 20) groups (86% vs. 100%, respectively). After a median follow-up of 36 (range: 9–53) months, the hypoxia group has significantly worse 1-year overall survival (91% vs. 100%), progression-free survival (77% vs. 95%), and local failure (18% vs. 5%) rates than the non-hypoxia group. Conclusions Despite not meeting the primary endpoint, our findings suggest that pretreatment tumor StO 2 is correlated with 1-year outcomes after RT, and OS imaging may be useful for identifying RT-resistant hypoxic tumors in HNSCC.
Authors
- Tomohiro Enokida (ORCID: https://orcid.org/0000-0001-6505-7591)
- Hidenari Hirata (ORCID: https://orcid.org/0000-0003-3130-6857)
- Hiroki Yamashita (ORCID: https://orcid.org/0000-0002-6190-7904)
- Hironori Sunakawa (ORCID: https://orcid.org/0000-0003-0792-9560)
- Masaki Nakamura (ORCID: https://orcid.org/0000-0002-4431-8892)
- Hiroshi Igaki (ORCID: https://orcid.org/0000-0001-7817-624X)
- Kento Tomizawa (ORCID: https://orcid.org/0000-0002-7822-2952)
- Madoka Sakuramachi (ORCID: https://orcid.org/0000-0002-4293-8617)
- Sadamoto Zenda (ORCID: https://orcid.org/0000-0002-0421-5805)
- Yusuke Yoda (ORCID: https://orcid.org/0000-0002-8488-4303)
- Tetsuo Akimoto (ORCID: https://orcid.org/0000-0003-0881-1345)
- Wataru Okano (ORCID: https://orcid.org/0000-0003-3915-4229)
- Y Saito
- S Abe
- Kazuto Matsuura
- Takeshi Fujisawa
- Shingo Sakashita
- Tomonori Yano
- Hidehiro Hojo
- Atsushi Motegi
- Makoto Tahara
Institutions
- Jikei University School of Medicine (JP)
- University of Tsukuba (JP)
- Saitama Cancer Center (JP)
- National Cancer Center Hospital East (JP)
- Tokyo National Hospital (JP)
- Gunma University Hospital (JP)
Publication Details
- Journal
- Communications Medicine
- Published
- 2026-07-01
- DOI
- https://doi.org/10.1038/s43856-026-01752-x
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00